Elsevier

Cellular Signalling

Volume 19, Issue 10, October 2007, Pages 2003-2012
Cellular Signalling

Review
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition

https://doi.org/10.1016/j.cellsig.2007.05.013Get rights and content

Abstract

Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a number of receptors. VEGFR-1 is required for the recruitment of haematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function. Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signalling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response. Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a number of diseases.

Introduction

Vascular endothelial growth factor (VEGF) represents a family of homodimeric glycoproteins which are critical for the embryonic development of the blood vascular system (vasculogenesis), lymphatic system (lymphangiogenesis) and in the formation of new blood vessels from pre-existing vessels (angiogenesis). In mammals, five different VEGF ligands have been identified and one parapoxvirus-encoded VEGF. These ligands bind, in an overlapping pattern, to three different, but structurally related, VEGF-receptor (VEGFR) tyrosine kinases. VEGFR-1 is critical for haematopoietic cell development, VEGFR-2 is critical for vascular endothelial cell development and VEGFR-3 critical for lymphatic endothelial cell development.

As our understanding of the role of VEGFs and VEGFRs in both physiological vascular development and pathological diseases, such as tumour angiogenesis, has grown over the last decade, a number of researchers have identified the signalling pathways downstream of the VEGF receptors. Selective activation of VEGFR-1 and VEGFR-2, coupled with gene silencing, has revealed that VEGFR-2 is the principal receptor transmitting VEGF signals in the vascular endothelium. This review will focus on our current understanding of VEGFR-2 signalling in endothelial cells and the clinical development of inhibitors of VEGFR-2 function.

Section snippets

The VEGF ligands

In mammals, the VEGF family consists of five members, VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PLGF). Structurally related proteins include parapoxvirus Orf VEGF, denoted VEGF-E [1], and snake venom VEGFs, denoted VEGF-F [2], [3]. VEGF-A was first described in 1983, by Senger and coworkers, as a tumour-secreted vascular-permeability factor (VPF) [4]. In 1989, Ferrara and Henzel reported the isolation and amino-acid sequence of an endothelial cell mitogen they named VEGF [5].

The VEGF receptors

VEGFs signal through cell surface receptor tyrosine kinases (Fig. 2). VEGFR-1 (Flt-1) is expressed on haematopoietic stem cells, monocytes, macrophages and vascular endothelial cells. VEGFR-2 (Flk-1/KDR) is expressed on vascular endothelial cells and lymphatic endothelial cells, whilst VEGFR-3, (Flt-4) expression is restricted to lymphatic endothelial cells. An alternatively spliced soluble VEGFR-1 variant (sVEGFR-1) is also expressed (for a review of VEGFR-1 and VEGFR-3, the reader is referred

VEGFR-2 structure

VEGFR-2 (kinase-insert domain receptor (KDR)/foetal liver kinase (Flk)-1) is a type III transmembrane kinase receptor, first isolated in 1991 by Terman and coworkers [22]. The human VEGFR-2 gene, located on chromosomes 4q11–q12, encodes a full-length receptor of 1356 amino acids [23]. It consists of an extracellular region composed of seven immunoglobulin (Ig)-like domains, a short transmembrane domain, and an intracellular region containing a tyrosine kinase domain, split by a 70-amino-acid

VEGFR-2 function

In murine embryogenesis, expression of VEGFR-2/Flk-1 is first detected at E7.0 in mesodermal blood island progenitors. Slightly later the gene is expressed in endothelial cell precursors and developing endothelial cells [41], [42], [43]. The critical role of VEGFR-2 in vascular development is highlighted by the fact that VEGFR-2−/− mice die at E8.5-9.5 due to defective development of blood islands, endothelial cells and haematopoietic cells [44]. In the adult, VEGFR-2 is expressed mostly on

VEGFR-2 intracellular signalling

A number of studies have shown that VEGFR-2 is the principal mediator of several physiological and pathological effects of VEGF-A on endothelial cells. These include proliferation, migration, survival and permeability. The intracellular signalling pathways mediating these effects downstream of VEGFR-2 activation are shown schematically in Fig. 4.

VEGFR-2 regulated gene expression

A number of studies have utilised techniques such as cDNA microarrays to identify genes which are upregulated in endothelial cells, following stimulation with VEGF [82], [83], [84], [85], [86]. Whilst a number of genes with known roles in angiogenesis were identified, such as Cox-2, a number of novel genes have also been identified, such as Down syndrome critical region-1 (DSCR-1). DSCR-1 was identified as the most highly upregulated gene in one study in VEGF stimulated endothelial cells [83],

VEGFR-2 signalling in disease and therapeutic inhibition

Angiogenesis plays a role in a number of pathological conditions, with VEGFR-2 signalling implicated in both tumour angiogenesis, and diabetic retinopathy [91]. Angiogenesis is crucial for tumour development as cancer cells have a relatively high metabolic demand for oxygen and nutrients to continue growing. Furthermore, the capillary and vascular network allows tumours to metastasise and spread to other sites in the body. Tumour vasculature is highly disorganised, and tumour blood flow is

Conclusions and perspectives

Research over the last decade has revealed the complexity of VEGFR signalling. Three different, but related, receptor tyrosine kinases regulate different aspects of vascular function. VEGFR-2 signalling has been the most intensively studied, as this receptor mediates the effects of VEGF-A on the vascular endothelium. This research has revealed a complex signalling mechanism regulating different aspects of physiological, and pathological angiogenesis. The development of anti-angiogenic drugs,

Acknowledgements

The authors are supported by grants from the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council/AstraZeneca (BBSRC/AZ CASE award), Cancer Research Wales (CRW) and North West Cancer Research Fund (NWCRF).

References (112)

  • Y. Yamazaki et al.

    J. Biol. Chem.

    (2003)
  • N. Ferrara et al.

    Biochem. Biophys. Res. Commun.

    (1989)
  • A.J. Potgens et al.

    J. Biol. Chem.

    (1994)
  • G.B. Whitaker et al.

    J. Biol. Chem.

    (2001)
  • A. Shinkai et al.

    J. Biol. Chem.

    (1998)
  • G. Fuh et al.

    J. Biol. Chem.

    (1998)
  • M. Dougher-Vermazen et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • S.A. Cunningham et al.

    Biochem. Biophys. Res. Commun.

    (1997)
  • R.L. Kendall et al.

    J. Biol. Chem.

    (1999)
  • L.W. Wu et al.

    J. Biol. Chem.

    (2000)
  • K. Holmqvist et al.

    J. Biol. Chem.

    (2004)
  • L. Lamalice et al.

    J. Biol. Chem.

    (2006)
  • R.D. Meyer et al.

    J. Biol. Chem.

    (2002)
  • B. Millauer et al.

    Cell

    (1993)
  • K.N. Meadows et al.

    J. Biol. Chem.

    (2001)
  • H.J. Liao et al.

    J. Biol. Chem.

    (2002)
  • K. Holmqvist et al.

    Cell. Signal.

    (2003)
  • A.J. Ridley et al.

    Cell

    (1992)
  • M. Dance et al.

    J. Biol. Chem.

    (2006)
  • M. Laramee et al.

    J. Biol. Chem.

    (2007)
  • H.P. Gerber et al.

    J. Biol. Chem.

    (1998)
  • A. Brunet et al.

    Cell

    (1999)
  • H.P. Gerber et al.

    J. Biol. Chem.

    (1998)
  • J. Tran et al.

    Biochem. Biophys. Res. Commun.

    (1999)
  • P.C. Brooks et al.

    Cell

    (1994)
  • B.P. Eliceiri et al.

    Mol. Cell

    (1999)
  • C. Wheeler-Jones et al.

    FEBS Lett.

    (1997)
  • E. Rennel et al.

    Exp. Cell. Res.

    (2007)
  • J. Folkman

    J. Pediatr. Surg.

    (2007)
  • B.A. Fine et al.

    Gynecol. Oncol.

    (2000)
  • D.J. Lyttle et al.

    J. Virol.

    (1994)
  • Y. Yamazaki et al.

    Mol. Divers.

    (2006)
  • D.R. Senger et al.

    Science

    (1983)
  • P. Carmeliet et al.

    Nature

    (1996)
  • N. Ferrara et al.

    Nature

    (1996)
  • V. Vincenti et al.

    Circulation

    (1996)
  • C.J. Robinson et al.

    J. Cell Sci.

    (2001)
  • D.O. Bates et al.

    Cancer Res.

    (2002)
  • J.E. Park et al.

    Mol. Biol. Cell

    (1993)
  • S. Lee et al.

    J. Cell Biol.

    (2005)
  • Y.A. Muller et al.

    Proc. Natl. Acad. Sci. U. S. A.

    (1997)
  • B. Berse et al.

    Mol. Biol. Cell

    (1992)
  • D. Shweiki et al.

    Nature

    (1992)
  • A. Minchenko et al.

    Cell. Mol. Biol. Res.

    (1994)
  • Y. Liu et al.

    Circ. Res.

    (1995)
  • A.K. Olsson et al.

    Nat. Rev., Mol. Cell Biol.

    (2006)
  • S. Soker et al.

    J. Cell Biochem.

    (2002)
  • B.I. Terman et al.

    Oncogene

    (1991)
  • S.N. Sait et al.

    Cytogenet Cell Genet.

    (1995)
  • M. Shibuya

    Biol. Chem.

    (2002)
  • Cited by (835)

    View all citing articles on Scopus
    View full text